Published in J Pharmacol Exp Ther on October 01, 1982
Characterization of alpha-adrenoceptors in the vasculature of the canine nasal mucosa. Br J Pharmacol (1986) 0.95
Selectivity and potency of 2-alkyl analogues of the alpha 2-adrenoceptor antagonist idazoxan (RX 781094) in peripheral systems. Br J Pharmacol (1984) 0.91
A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin Pharmacol Ther (2010) 2.74
Studies on RX 781094: a selective, potent and specific antagonist of alpha 2-adrenoceptors. Br J Pharmacol (1983) 2.21
PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med (1984) 2.09
Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. Eur J Pharmacol (1991) 1.85
IGPHARM: interactive graphic package for pharmacokinetic analysis. Comput Biomed Res (1978) 1.71
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res (1983) 1.67
The potassium channel opener cromakalim (BRL 34915) activates ATP-dependent K+ channels in isolated cardiac myocytes. Biochem Biophys Res Commun (1988) 1.65
Pharmacokinetics of N-demethyldiazepam in patients suffering from insomnia and treated with nortriptyline. Br J Clin Pharmacol (1975) 1.63
Central alpha- and beta-adrenoceptors modifying arterial blood pressure and heart rate in conscious cats. Br J Pharmacol (1974) 1.62
A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat (1995) 1.54
Joint modeling of efficacy, dropout, and tolerability in flexible-dose trials: a case study in depression. Clin Pharmacol Ther (2012) 1.41
Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther (1997) 1.41
Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol (1974) 1.40
Evidence for, and nature of, the tonic inhibitory influence of habenulointerpeduncular pathways upon cerebral dopaminergic transmission in the rat. Brain Res (1986) 1.39
Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol (2008) 1.28
Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol (1985) 1.26
Tissue levels of several radiolabelled beta-adrenoceptor antagonists after intravenous administration in rats. Arch Int Pharmacodyn Ther (1979) 1.25
Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet (1976) 1.25
Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch Pharmacol (1984) 1.21
Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390. Brain Res (1986) 1.21
PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. J Nucl Med (1991) 1.17
Differential effects of prazosin on the pre- and postsynaptic alpha-adrenoceptors in the rat and dog [proceedings]. Br J Pharmacol (1977) 1.15
Effects of prazosin and phentolamine on cardiac presynaptic alpha-adrenoceptors in the cat, dog and rat. Clin Exp Hypertens (1978) 1.15
Origin of dopaminergic innervation of the rat hippocampal formation. Neurosci Lett (1980) 1.15
Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther (1997) 1.13
Influence of age on mianserin pharmacokinetics. Psychopharmacology (Berl) (1982) 1.13
Studies on the mechanism of the vasodilator effects of prazosin in dogs and rabbits. Eur J Pharmacol (1978) 1.13
alpha 2-Adrenoceptor agonists induced mydriasis in the rat by an action within the central nervous system. Br J Pharmacol (1983) 1.11
Cardiovascular effects of beta-adrenoreceptor blocking agents after intracerebroventricular administration in conscious normotensive cats. Clin Exp Pharmacol Physiol (1975) 1.10
Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther (1980) 1.09
Autoradiographic distribution of the D1 agonist [3H]SKF 38393, in the rat brain and spinal cord. Comparison with the distribution of D2 dopamine receptors. Neuroscience (1986) 1.09
Cardiovascular effects of prazosin in dogs. Clin Sci Mol Med Suppl (1976) 1.09
Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol (1998) 1.09
Quantitative motor assessment in FALS mice: a longitudinal study. Neuroreport (1997) 1.09
Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther (1988) 1.07
Potassium channel openers act through an activation of ATP-sensitive K+ channels in guinea-pig cardiac myocytes. Pflugers Arch (1989) 1.07
Preliminary studies on SL 75212, a new potent cardioselective beta-adrenoceptor antagonist [proceedings]. Br J Pharmacol (1979) 1.06
Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther (1987) 1.06
Dopamine deficiency in the cerebral cortex in Parkinson disease. Neurology (1982) 1.05
Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol (1987) 1.05
The pharmacology of prazosin, a novel antihypertensive agent. Life Sci (1980) 1.03
Dopaminergic A10 neurones are involved in cognitive functions. Nature (1980) 1.01
Cardiovascular characterization of DA-1 and DA-2 dopamine receptor agonists in anesthetized rats. Clin Exp Hypertens A (1987) 1.01
Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther (1990) 1.01
Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology (1987) 1.00
Urethane inhibits cardiovascular responses mediated by the stimulation of alpha-2 adrenoceptors in the rat. J Pharmacol Exp Ther (1982) 1.00
Central adrenoreceptors and the control of arterial blood pressure. Clin Exp Pharmacol Physiol (1975) 1.00
Adrenoceptors in the central nervous system concerned with cardiovascular control. J Pharm Pharmacol (1972) 0.99
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther (2003) 0.99
Inhibitory influence of GABA on central serotonergic transmission. Involvement of the habenulo-raphé pathways in the GABAergic inhibition of ascending cerebral serotonergic neurons. Brain Res (1985) 0.99
Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br J Pharmacol (1997) 0.99
Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: effects of drugs affecting noradrenergic transmission. J Neurochem (1986) 0.99
Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation (1992) 0.99
The new K+ channel opener Aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther (1991) 0.98
Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res (1987) 0.98
Differential responsiveness of the rat dorsal and median raphe 5-HT systems to 5-HT1 receptor agonists and p-chloroamphetamine. Synapse (1990) 0.98
-Adrenergic receptors in the central nervous system of the cat concerned with control of arterial blood pressure and heart rate. Nat New Biol (1973) 0.98
Imaging of primary and remote ischaemic and excitotoxic brain lesions. An autoradiographic study of peripheral type benzodiazepine binding sites in the rat and cat. Brain Res (1988) 0.97
SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. J Pharmacol Exp Ther (2001) 0.97
Adaptive-optimal design in PET occupancy studies. Clin Pharmacol Ther (2010) 0.96
Presynaptic alpha-adrenoreceptors; in vitro methods and preparations utilised in the evaluation of agonists and antagonists. J Auton Pharmacol (1980) 0.96
Characterization of alpha-adrenoceptors in the vasculature of the canine nasal mucosa. Br J Pharmacol (1986) 0.95
In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. Arzneimittelforschung (1995) 0.95
Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part I: Subclassification and functional description. Life Sci (1982) 0.95
K+ channel openers and 'natural' cardioprotection. Trends Pharmacol Sci (1992) 0.95
"Calcium antagonists": a class of drugs with a bright future. Part II. Determination of basic pharmacological properties. Life Sci (1984) 0.95
Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol (1970) 0.95
Indoleaminergic mechanisms in brain vessels; localization, concentration, uptake and in vitro responses of 5-hydroxytryptamine. Acta Physiol Scand (1984) 0.93
Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother (1991) 0.93
Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease. Naunyn Schmiedebergs Arch Pharmacol (1985) 0.93
Central serotonergic nerves project to the pial vessels of the brain. Nature (1983) 0.93
Vasodilator activity of endothelin-1 and endothelin-3: rapid development of cross-tachyphylaxis and dependence on the rate of endothelin administration. J Pharmacol Exp Ther (1990) 0.93
gamma-Aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor. J Pharmacol Exp Ther (1982) 0.93
Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. J Pharmacol Exp Ther (1990) 0.93
Cellular pharmacology of potassium channel openers in vascular smooth muscle. Cardiovasc Res (1994) 0.93
Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol Pharmacol (1995) 0.92
The effects of prazosin on the clonidine induced hypotension and bradycardia in rats and sedation in chicks [proceedings]. Br J Pharmacol (1978) 0.92
Time-course analysis of the cardiovascular effects of clonidine resulting from the activation of cardiac pre- and vascular postsynaptic alpha-adrenoceptors in the pithed rat [proceedings]. Br J Pharmacol (1978) 0.92
The mechanism of the antihypertensive action of -methyldopa in hypertensive rats. Eur J Pharmacol (1973) 0.91
Selectivity and potency of 2-alkyl analogues of the alpha 2-adrenoceptor antagonist idazoxan (RX 781094) in peripheral systems. Br J Pharmacol (1984) 0.91
Increase in omega 3 (peripheral-type benzodiazepine) binding site densities in different types of human brain tumours. A quantitative autoradiography study. Acta Neurochir (Wien) (1992) 0.91
Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol (1992) 0.91
Studies on the bradycardia induced by (-)- -trans-tetrahydrocannabinol in anesthetized dogs. Eur J Pharmacol (1973) 0.91
Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol. J Pharmacol Exp Ther (1987) 0.90
Systemic and regional hemodynamic characterization of alpha-1 and alpha-2 adrenoceptor agonists in pithed rats. J Pharmacol Exp Ther (1987) 0.89
"Calcium antagonists": a class of drugs with a bright future. Part I. Cellular calcium homeostasis and calcium as a coupling messenger. Life Sci (1983) 0.89